Sprim & Tikehau contribute $50mn toward medtech & life science sectors
Date: 2018-03-13   Author: Saipriya Iyer  Category: #news

Sprim & Tikehau contribute $50mn toward medtech & life science sectors

Tikehau Capital, a private equity firm headquartered in France, has scarcely formed an association with Sprim Ventures, an investor in early stage health solutions. The alliance aims to introduce a USD 50 million early-phase venture capital fund targeting medtech & life sciences firms in Singapore. Industry analysts speculate that the combined entity referred as TKS1 is planning to provide funds to new firms, whose objective is to deliver effective healthcare solutions. The new establishment is also set up to significantly contribute toward the rapid development of therapeutics.

Tikehau Capital handles nearly EUR 13.8 billion of assets as well as asset classes through its asset management division Tikehau IM. Bruno de Pampelonne, Chairperson of Tikehau IM, has stated that with Singapore emerging as an innovation hub, both Sprim and Tikehau have selected medtech & life science firms as their key VC investment destinations. He further added that supportive government policies, a strong R&D ecosystem, and the presence of numerous research institutes & startups have made the country a global hub for carrying out healthcare research activities.

As per reliable reports, TKS1 has announced that it has already funded five firms, namely, ObvioHealth, Travecta Therapeutics, Evid Science, Fibronostics, and Babynostics. TKS1 is likely to focus on initial-stage investments ranging from USD 5,00,000 to USD 5 million across medtech & life science sectors.

The co-founder of Sprim Ventures, Michael Shleifer has announced that through Tikehau Capital support and its own expertise across the healthcare sector, TKS1 will be able to offer exceptional services to the patients & physicians. He asserted that the strategic partnership will assist both the firms in contributing notably towards the growth of the healthcare industry.

Analysts state that this deal forms a part of the lucrative investments witnessed by the medical care sector since the last few years. AltAssets quotes instances of the same, claiming that KKR raised funds worth USD 598 million for its healthcare program while Lilly Asia Ventures closed its fourth healthcare fund round at USD 450 million recently.



About Author


Saipriya Iyer

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

More from Saipriya


Post Recommendents

Global Angular Contact Ball Bearings Industry Market – Porter’s Five Forces Strategy Analysis and Forecast 2025
Author: Sachin Pashte

The New Research Report on Global Angular Contact Ball Bearings Industry Market till 2025 added by Market Study Report LLC studies the current and upcoming Market Size, Share, Demand, Growth Trend and Forecast.

The research report on Angular...


Ladder Industry Market Projection By Key Players, Status, Growth, Revenue, SWOT Analysis Forecast 2025
Author: Sachin Pashte

Market Study Report adds new report on Global Ladder Industry Market analysis 2020-2025. The report focuses on global major leading industry players with information such as company profiles, end users/applications, product and specification.

<...


DNA Repair Drugs Industry Market 2020 | Analysis by Industry Trends, Size, Share, Company Overview, Growth, Development and Forecast by 2025
Author: Sachin Pashte

Global DNA Repair Drugs Industry Market Report available at MarketStudyReport.com gives an industry overview of the DNA Repair Drugs Industry, which covers product scope, market revenue, opportunities, growth rate, sales volumes and figures. The r...